Youmna Lahoud

For decades, the lupus community has faced a difficult reality: targeted treatment options are limited, with only two biologics approved in the U.S. to treat one of the most common forms of the condition, systemic lupus erythematosus (SLE).1 For the 5 million people globally living with this highly heterogeneous set of autoimmune diseases, the variability in their experiences – from ambiguity of symptoms to therapy response – lead to delays in diagnosis and care.2 Their challenges extend...

Abstract Systemic lupus erythematosus (SLE) is a disease of high unmet therapeutic need. The challenge of accurately measuring clinically meaningful responses to treatment has hindered progress towards positive outcomes in SLE trials, impeding the approval of potential new therapies.